PPT-Measles and Rubella Serosurveys

Accelerating Progress Towards Measles and Rubella Elimination 23 June 2016 Geneva Switzerland Minal K Patel WHO HQ IVBEPI Background Growing demand for periodic crosssectional surveys to identify population immunity gaps. Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . Tenth Annual  Measles Initiative Meeting . September 13-14, 2011 Washington, DC. Sergei Deshevoi. WHO European Region . 2. Presentation outline. Regional goal and strategy. Progress towards goal. Challenges in reaching the goal in 2015. --Who We Are--. Stephen Cochi, . MD, MPH. Global . Immunization Division. Centers . for . Disease Control & Prevention. What is the Measles & Rubella Initiative? . Anne Ray Charitable Trust. WHO Western Pacific Region. UNICEF East Asia and Pacific Region. 1. 21 June 2016. Geneva, Switzerland. Regional Measles and Rubella Goals. 2003. : Measles elimination to be used to strengthen routine immunization . Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . Accelerating progress towards measles and rubella elimination. Geneva, Switzerland 21-23 June 2016 . Jenny Rota, WHO consultant. Goal is to update information to reflect current responsibilities of the network, provide best practices, resources and guidelines. Dr. Kimberly M. Thompson. Kid Risk, Inc., www.kidrisk.org. Topics. Context. I. ntegrated dynamic disease and economic . modeling. Discussion. http://www.wpro.who.int/vietnam/topics/immunization/measles_rubella/measles_rubella_big.png?ua=1. 2020. . Summary of the . Findings . and Implementation Status . Dr Kaushik . Banerjee. M&RI Partners' Meeting. Washington DC. 7 September 2017. 1. Objectives . of . the Review. To provide a candid review of progress . Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . Measles and Rubella Annual Partners Meeting, September 15-16 2015. Background. The MRI FRR is developed by the M&RI FRR/RMAWG. Country population data is drawn from UNDP estimates. Vaccine type and timing of SIAs is from countries . easily through the air, or through contact with uids in the nose or throat. The viruses can pass from person to person by coughing, sneezing, or sharing food or drinks. Children may become inf MEA R) VACCINE What is the measles, mump and rubella (MMR) vaccine? The MMR vaccine protects against three diseases: measles, mumps and rubella (german measles). The vaccine is approved by He alth C Opening Comments & Perspectives. Dr. Suresh Jadhav. Executive Director. Serum Institute of India Pvt. Ltd.,. ssj@seruminstitute.com. . We, at Serum Institute of India Pvt. Ltd., feel proud of being a partner to PAHO / WHO in achieving what is designated to be a historical achievement in eradication of Measles & Rubella diseases from the Americas..  .  . Frequently Asked Questions. For Use of Teachers. Government of India has decided to introduce. measles-rubella (MR). vaccine. . The vaccine will be launched through a campaign,. to be followed by inclusion of the MR vaccine.